The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
|Videos|August 4, 2022
Hospital stays shorter with intracorporeal robotic vs open cystectomy
Author(s)Urology Times staff
Advertisement
Pramit Khetrapal, MD, academic clinical fellow in Urology, Barts Health NHS Trust discusses the background and results of the abstract, “Results of the intracorporeal robotic vs open cystectomy multi-centre randomised trial,” which he presented at the 2022 AUA Annual Meeting (
Advertisement
Related to this article
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Final phase 3 CA017-078 data show perioperative nivolumab plus GC did not significantly improve pCR (39.1% vs 29.6%) or EFS (HR, 0.94) vs GC alone in MIBC.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
2
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
3
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
4
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
5